Arbutus Biopharma Corporation $ABUS Stake Increased by Rubric Capital Management LP

Rubric Capital Management LP grew its holdings in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 320.6% in the first quarter, Holdings Channel.com reports. The firm owned 6,626,389 shares of the biopharmaceutical company’s stock after purchasing an additional 5,051,013 shares during the period. Rubric Capital Management LP’s holdings in Arbutus Biopharma were worth $29,819,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ABUS. Morgan Stanley grew its holdings in shares of Arbutus Biopharma by 9.2% during the fourth quarter. Morgan Stanley now owns 26,702,776 shares of the biopharmaceutical company’s stock valued at $128,440,000 after buying an additional 2,252,164 shares in the last quarter. Two Seas Capital LP boosted its position in Arbutus Biopharma by 14.5% during the 4th quarter. Two Seas Capital LP now owns 12,589,158 shares of the biopharmaceutical company’s stock worth $60,554,000 after acquiring an additional 1,597,897 shares during the period. State Street Corp boosted its position in Arbutus Biopharma by 44.2% during the 4th quarter. State Street Corp now owns 5,908,211 shares of the biopharmaceutical company’s stock worth $28,418,000 after acquiring an additional 1,809,893 shares during the period. ADAR1 Capital Management LLC grew its stake in Arbutus Biopharma by 86.5% during the 4th quarter. ADAR1 Capital Management LLC now owns 5,415,109 shares of the biopharmaceutical company’s stock valued at $26,047,000 after acquiring an additional 2,511,883 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Arbutus Biopharma by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 3,677,307 shares of the biopharmaceutical company’s stock valued at $17,691,000 after acquiring an additional 11,145 shares in the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ABUS. Wall Street Zen upgraded Arbutus Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Arbutus Biopharma in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Arbutus Biopharma presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Arbutus Biopharma Trading Up 0.7%

NASDAQ ABUS opened at $4.41 on Tuesday. Arbutus Biopharma Corporation has a 1-year low of $3.24 and a 1-year high of $5.38. The firm’s fifty day simple moving average is $4.53 and its 200-day simple moving average is $4.41. The company has a market capitalization of $871.15 million, a PE ratio of 5.31 and a beta of 0.62.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter. Arbutus Biopharma had a return on equity of 129.32% and a net margin of 83.95%.The firm had revenue of $179.13 million during the quarter. As a group, analysts predict that Arbutus Biopharma Corporation will post -0.16 EPS for the current year.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.